Combination of TATE and PD-1 Inhibitor in Liver Cancer
Recruiting now · Phase 2
Conditions studied: Hepatocellular Carcinoma, Gastric Cancer
In brief
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Key facts
- Study ID
- NCT03259867
- Run by
- Teclison Ltd.
- People needed
- 54
- Starts
- 2017-07-01
- Expected to finish
- 2027-06-30
- Last updated by the study team
- 2026-04-16
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, Irvine — Orange, California, United States (enrolling)
- University of Oklahoma Health Science Center — Oklahoma City, Oklahoma, United States (enrolling)
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.